Literature DB >> 7138592

Hypertrophic osteoarthropathy in cyanotic congenital heart disease: its prevalence and relationship to bypass of the lung.

M Martínez-Lavín, M Bobadilla, J Casanova, F Attié, M Martínez.   

Abstract

The frequency of hypertrophic osteoarthropathy in cyanotic congenital heart disease has previously been considered to be very low. Only a few isolated reports have described such an association. We studied 32 consecutive patients older than 6 years with various types of cyanotic congenital heart disease and examined each case for hypertrophic osteoarthropathy. We also assessed the role of the altered cardiopulmonary hemodynamics in the development of hypertrophic osteoarthropathy by means of cardiac catheterization. Our results showed that 31% of the patients had hypertrophic osteoarthropathy. When the hemodynamic parameters of the group of patients with hypertrophic osteoarthropathy were compared with those of the remaining patients, we found significant differences in the systemic blood flow (P less than or equal to 0.05), right-to-left shunt (P less than or equal to 0.05), and arterial oxygen unsaturation (P less than or equal to 0.005). Thus, we found a much higher prevalence of hypertrophic osteoarthropathy in patients with cyanotic congenital heart disease than has previously been recognized. The development of hypertrophic osteoarthropathy is related to the degree of bypass of the lung. This is consistent with the concept that hypertrophic osteoarthropathy results from mediators in the systemic venous circulation that escape inactivation in the pulmonary capillary bed.

Entities:  

Mesh:

Year:  1982        PMID: 7138592     DOI: 10.1002/art.1780251007

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

1.  Bone abnormalities and severe arthritis in pachydermoperiostosis.

Authors:  R G Cooper; A J Freemont; M Riley; P J Holt; D C Anderson; M I Jayson
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

2.  Hypertrophic osteoarthropathy: endothelium and platelet function.

Authors:  F Silveri; R De Angelis; F Argentati; D Brecciaroli; S Muti; C Cervini
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

Review 3.  Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy.

Authors:  Sheila Nguyen; Mehrnaz Hojjati
Journal:  Clin Rheumatol       Date:  2010-10-09       Impact factor: 2.980

4.  Hypertrophic osteoarthropathy and congenital heart disease: this is not casual.

Authors:  Ester Ferreira; Isabel Camões
Journal:  BMJ Case Rep       Date:  2013-09-18

5.  Laterality defects other than situs inversus totalis in primary ciliary dyskinesia: insights into situs ambiguus and heterotaxy.

Authors:  Adam J Shapiro; Stephanie D Davis; Thomas Ferkol; Sharon D Dell; Margaret Rosenfeld; Kenneth N Olivier; Scott D Sagel; Carlos Milla; Maimoona A Zariwala; Whitney Wolf; Johnny L Carson; Milan J Hazucha; Kimberlie Burns; Blair Robinson; Michael R Knowles; Margaret W Leigh
Journal:  Chest       Date:  2014-11       Impact factor: 9.410

6.  Case report 701: Prostaglandin E1 (PGE1) periostitis.

Authors:  R F Rowley; J P Lawson
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

Review 7.  Paraneoplastic rheumatic disorders: a review.

Authors:  R C Butler; J M Thompson; A C Keat
Journal:  J R Soc Med       Date:  1987-03       Impact factor: 18.000

8.  Hypertrophic osteopathy in a cat with a concurrent injection-site sarcoma.

Authors:  Raquel Salgüero; Jackie Demetriou; Fernando Constantino-Casas; Michael Herrtage
Journal:  JFMS Open Rep       Date:  2015-07-06

9.  Digital clubbing.

Authors:  Malay Sarkar; D M Mahesh; Irappa Madabhavi
Journal:  Lung India       Date:  2012-10

10.  Hypertrophic osteopathy in a cat with cardiac interventricular septal defect.

Authors:  Felipe Auatt Batista de Sousa; Matheus Viezzer Bianchi; Paula Augusto Taunde; Marcele Bettim Bandinelli; Rochana Rodrigues Fett; David Driemeier; Saulo Petinatti Pavarini
Journal:  J Vet Sci       Date:  2019-09       Impact factor: 1.672

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.